Welcome to our dedicated page for Geron SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Geron’s SEC disclosures is no small task. Clinical trial footnotes, preferred stock conversions, and imetelstat milestones sprawl across hundreds of pages. Investors searching “Geron quarterly earnings report 10-Q filing,” “Geron insider trading Form 4 transactions,” or simply “Geron SEC filings explained simply” often spend hours hunting for one number: cash runway. Our platform removes that friction.
Stock Titan’s AI-powered summaries pinpoint the R&D burn rate, partnership revenue, and trial progress buried in every document. Whether you need “Geron 8-K material events explained” after an unexpected efficacy update or a “Geron annual report 10-K simplified” before your valuation model, we translate technical jargon into plain English within seconds. Real-time alerts stream “Geron Form 4 insider transactions real-time,” flagging when executives adjust positions so you never miss a signal.
From proxy to prospectus, every filing type is covered:
- 10-K and 10-Q: drill into segment spending with “Geron earnings report filing analysis”.
- Form 4: monitor “Geron executive stock transactions Form 4” for buying or selling trends.
- DEF 14A: review “Geron proxy statement executive compensation” without spreadsheets.
- 8-K: catch material trial announcements the moment they hit EDGAR.
Use our expert insights to compare quarter-over-quarter R&D shifts, assess dilution risk from new equity offerings, and understand pipeline milestones—all without sifting through medical jargon. If you’ve ever searched “understanding Geron SEC documents with AI,” you’ve just found the answer.
DSS, Inc. (NYSE American: DSS) disclosed in an 8-K filed on July 1, 2025 that it dismissed Grassi & Co., CPAs, P.C. as its independent registered public accounting firm, effective June 27, 2025. The Board of Directors approved the decision and, on the same date, appointed HTL International, LLC as the new auditor.
The company states that, for the engagement period from July 1, 2022 through June 27, 2025, there were no disagreements with Grassi concerning accounting principles, financial-statement disclosures, or audit scope and procedures that would have required reference in Grassi’s reports. DSS also confirms that, during the last two fiscal years and up to the engagement date, it did not consult HTL on any accounting matters or the type of audit opinion to be rendered, and there were no reportable events under Item 304(a)(1)(v) of Regulation S-K.
Exhibit 16.1 will contain Grassi’s letter to the SEC confirming the disclosures. The change suggests a routine auditor transition rather than a reaction to a dispute, but investors may monitor the first audit cycle for any adjustments or restatements under the new firm.
Geron Corporation (ticker GERN) has filed a Form S-8 to register an additional 26 million shares of common stock for employee benefit purposes:
- 20 million shares for the 2018 Equity Incentive Plan
- 6 million shares for the 2014 Employee Stock Purchase Plan (ESPP)
For investors, the filing signals continued use of equity-based compensation, which can motivate employees but may incrementally dilute existing shareholders as the newly registered shares are issued over time.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
What is Geron Corp's primary focus?
How does the company plan to treat cancers?
What makes Geron Corp's approach unique?
How does Geron generate revenue?
How is Geron positioned within the oncology research space?
What therapeutic areas are targeted by imetelstat?
